Mineralys Therapeutics, Inc. (MLYS)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Mineralys: Pre-NDA Feedback Sets Stage For A Pivotal 2026
Mineralys (MLYS) is transitioning to a pre-commercial stage, supported by robust Phase 3 data and a strengthened cash position of $593.6 million. MLYS's lorundrostat demonstrated significant efficacy in lowering systolic blood pressure, with compelling results in both real-world and specialty settings. Regulatory risk is reduced following positive pre-NDA FDA feedback and JAMA recognition, with NDA submission expected late 2025 or early 2026.
Wall Street Analysts Think Mineralys Therapeutics, Inc. (MLYS) Could Surge 27.55%: Read This Before Placing a Bet
The mean of analysts' price targets for Mineralys Therapeutics, Inc. (MLYS) points to a 27.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Mineralys Therapeutics, Inc. (MLYS) Q3 2025 Earnings Call Transcript
Mineralys Therapeutics, Inc. ( MLYS ) Q3 2025 Earnings Call November 10, 2025 4:30 PM EST Company Participants Jon Congleton - President, CEO & Director Adam Levy - CFO & Secretary David Rodman - Chief Medical Officer Eric Warren Conference Call Participants Daniel Ferry - Lifesci Advisors, LLC Umer Raffat - Evercore ISI Institutional Equities, Research Division Jin Law - Goldman Sachs Group, Inc., Research Division Alice Nettleton - BofA Securities, Research Division Jayed Momin - Stifel, Nicolaus & Company, Incorporated, Research Division Mohit Bansal - Wells Fargo Securities, LLC, Research Division Rami Katkhuda - LifeSci Capital, LLC, Research Division Presentation Operator Greetings, and welcome to Mineralys Third Quarter 2025 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.
Mineralys: Lorundrostat Continues To Deliver Hypertension Market Expansions
Mineralys Therapeutics, Inc. advances lorundrostat, its lead aldosterone inhibitor, for uncontrolled and resistant hypertension with pivotal Phase 3 successes. Mineralys achieved positive Phase 2 results in CKD patients with hypertension, supporting NDA submission and expanding lorundrostat's potential patient base. A pre-NDA meeting with the FDA is set for Q4 2025, with additional Phase 2 data in OSA-hypertension expected in Q1 2026 as further catalysts.
What Makes Mineralys Therapeutics, Inc. (MLYS) a Strong Momentum Stock: Buy Now?
Does Mineralys Therapeutics, Inc. (MLYS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Believe Mineralys Therapeutics, Inc. (MLYS) Could Rally 149.66%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 149.7% in Mineralys Therapeutics, Inc. (MLYS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Mineralys Therapeutics, Inc. (MLYS) Q2 2025 Earnings Call Transcript
Mineralys Therapeutics, Inc. (NASDAQ:MLYS ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Adam Scott Levy - CFO & Secretary Eric Warren - Chief Commercial Officer Jon Congleton - President, CEO & Director Daniel Ferry - Managing Director, Lifesci Advisors, LLC Conference Call Participants Alice Jennifer Nettleton - BofA Securities, Research Division Jayed Momin - Stifel, Nicolaus & Company, Incorporated, Research Division Matthew Coleman Caufield - H.C. Wainwright & Co, LLC, Research Division Michael DiFiore - Unidentified Company Evercore - Unidentified Company Rami Azeez Katkhuda - LifeSci Capital, LLC, Research Division Richard J.
Mineralys Therapeutics, Inc. (MLYS) Upgraded to Buy: Here's Why
Mineralys Therapeutics, Inc. (MLYS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Does Mineralys Therapeutics, Inc. (MLYS) Have the Potential to Rally 154.21% as Wall Street Analysts Expect?
The mean of analysts' price targets for Mineralys Therapeutics, Inc. (MLYS) points to a 154.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here's Why Momentum in Mineralys Therapeutics, Inc. (MLYS) Should Keep going
Mineralys Therapeutics, Inc. (MLYS) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Here's Why Mineralys Therapeutics, Inc. (MLYS) is a Great Momentum Stock to Buy
Does Mineralys Therapeutics, Inc. (MLYS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Mineralys Therapeutics, Inc. (MLYS) Q1 2025 Earnings Conference Call Transcript
Mineralys Therapeutics, Inc. (NASDAQ:MLYS ) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants Dan Ferry - LifeSci Advisors, IR Jon Congleton - CEO Dave Rodman - Chief Medical Officer Adam Levy - CFO Conference Call Participants Michael DiFiore - Evercore ISI Richard Law - Goldman Sachs Seamus Fernandez - Guggenheim Rami Katkhuda - LifeSci Capital Operator Good afternoon, ladies and gentlemen, and welcome to the Mineralys First Quarter 2025 Earnings Conference Call. At this time, all lines are in listen-only mode.
